×
About 455 results

ALLMedicine™ Alveolar Soft Part Sarcoma Center

Research & Reviews  139 results

Sonographic imaging features of alveolar soft part sarcoma: Case series and literature ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678532
Medicine Li W, Zhang S et. al.

Nov 20th, 2022 - Alveolar soft part sarcoma (ASPS) is a rare tumor but potentially fatal condition. Understanding the imaging and clinical features of ASPS is of certain value for preoperative qualitative diagnosis and clinical treatment of tumors. Nevertheless, t...

Fine-needle aspiration of scalp masses: A review of 30 cases.
https://doi.org/10.1002/dc.25073
Diagnostic Cytopathology; Doan M, Ramani NS et. al.

Nov 6th, 2022 - Scalp masses are often the initial presentation of a widely disseminated malignancy. Fine-needle aspiration (FNA) is an optimal method for obtaining an accurate tissue diagnosis, in these patients with initial presentation and those with a known m...

Lingual Alveolar Soft Part Sarcoma in a 78-Year-Old Woman: A Case Report and Comprehens...
https://doi.org/10.1007/s12105-022-01505-x
Head and Neck Pathology; Aksionau A, Dela Cruz NE et. al.

Oct 28th, 2022 - Alveolar soft part sarcoma (ASPS) is a rare translocation-related soft tissue sarcoma, occurring mainly in the limbs and trunk in young adults and adolescents. ASPS is rarely seen in the head and neck and one fourth of those cases described are to...

Randomized Phase 2 Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma.
https://doi.org/10.1158/1078-0432.CCR-22-2145
Clinical Cancer Research : an Official Journal of the Ame... Nguyen J, Takebe N et. al.

Oct 28th, 2022 - Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor with few treatment options. We designed a phase 2 randomized trial to determine the activity and tolerability of single-agent cediranib or sunitinib in patients with advanced metas...

Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcoma...
https://doi.org/10.1158/1078-0432.CCR-22-2509
Clinical Cancer Research : an Official Journal of the Ame... Moyers JT, Carmagnani Pestana R et. al.

Oct 27th, 2022 - Recently the Connective Tissue Oncology Society published consensus guidelines for recognizing Ultrarare Sarcomas (URS), defined as sarcomas with an incidence <1 per 1,000,000. We assessed the outcomes of 56 patients with soft tissue, and 21 with ...

see more →

Clinicaltrials.gov  15 results

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
https://clinicaltrials.gov/ct2/show/NCT01391962

Oct 14th, 2022 - Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS. Little is known with regards to relevan...

Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study
https://clinicaltrials.gov/ct2/show/NCT05333458

Jul 6th, 2022 - PRIMARY OBJECTIVE: I. Determine the overall response rate (by Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1) for selinexor in combination with atezolizumab in immune checkpoint inhibitor (ICI)-naive patients with alveolar so...

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma
https://clinicaltrials.gov/ct2/show/NCT03141684

Jun 30th, 2022 - PRIMARY OBJECTIVES: I. Determine the objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 of atezolizumab in patients with advanced alveolar soft part sarcoma (ASPS) in adult subjects >= 18 year...

Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
https://clinicaltrials.gov/ct2/show/NCT00942877

Mar 22nd, 2022 - Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS. Little is known with regards to relevan...

see more →

News  28 results

Durvalumab Plus Tremelimumab Elicits Favorable PFS Rates in Advanced Sarcomas
https://www.onclive.com/view/durvalumab-plus-tremelimumab-elicits-favorable-pfs-rates-in-advanced-sarcomas

Aug 23rd, 2022 - The combination of durvalumab (Imfinzi) and tremelimumab demonstrated positive progression-free survival (PFS) and overall survival (OS) rates with expected toxicity data in patients with advanced or metastatic soft tissue and bone sarcomas, accor...

Investigators Express Confidence in a Novel TKI That Targets Rare Sarcomas
https://www.onclive.com/view/investigators-express-confidence-in-a-novel-tki-that-targets-rare-sarcomas

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Anlotinib, a novel tyrosine kinase inhibitor capable of mounting a multipronged attack against oncogenic processes, is being tested in rare soft tissue sarcoma subtypes where patients have limited therapeutic options. ...

Dr. Trent on Research Efforts in Bone and Soft Tissue Sarcomas
https://www.onclive.com/view/dr-trent-on-research-efforts-in-bone-and-soft-tissue-sarcomas

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD, professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses research efforts in bone and soft tissue sarcomas. Recently, several adv...

NY-ESO-1, MAGE-A4 Among Key Targets in Sarcoma Research
https://www.onclive.com/view/nyeso1-magea4-among-key-targets-in-sarcoma-research

Oct 6th, 2021 - Neeta Somaiah, MD Therapeutic advances in soft tissue sarcoma have occurred across several subtypes, and more research efforts continue to be conducted with novel agents targeting NY-ESO-1 and MAGE-A4, for example, explained Neeta Somaiah, MD. F...

Key Advances in Sarcoma Lead to More Personalized Medicine Efforts
https://www.onclive.com/view/key-advances-in-sarcoma-lead-to-more-personalized-medicine-efforts

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Soft tissue sarcoma treatments have significantly advanced within the past year with new available agents, others in the pipeline, and the continued search for biomarkers to make treatment more personalized for patients...

see more →